Cargando…

Real-world experience of monoclonal antibodies in mild-to-moderate COVID-19 patients at a tertiary care center

BACKGROUND: Neutralizing antibodies cocktail (casirivimab and imdevimab) has received emergency use authorization recommendation by Food and Drug Administration (FDA) and WHO for mild-to-moderate COVID-19 infection in specific high-risk groups. Antibodies cocktail has shown promising results in prev...

Descripción completa

Detalles Bibliográficos
Autores principales: Marwah, Vikas, Choudhary, Robin, Adhikari, Sudipt, Pemmaraju, Arpita, Menon, A.S., Manrai, Manish, Ajai Kumar, Tentu, Verma, Shipra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193195/
https://www.ncbi.nlm.nih.gov/pubmed/37360888
http://dx.doi.org/10.1016/j.mjafi.2023.03.006
_version_ 1785043789274939392
author Marwah, Vikas
Choudhary, Robin
Adhikari, Sudipt
Pemmaraju, Arpita
Menon, A.S.
Manrai, Manish
Ajai Kumar, Tentu
Verma, Shipra
author_facet Marwah, Vikas
Choudhary, Robin
Adhikari, Sudipt
Pemmaraju, Arpita
Menon, A.S.
Manrai, Manish
Ajai Kumar, Tentu
Verma, Shipra
author_sort Marwah, Vikas
collection PubMed
description BACKGROUND: Neutralizing antibodies cocktail (casirivimab and imdevimab) has received emergency use authorization recommendation by Food and Drug Administration (FDA) and WHO for mild-to-moderate COVID-19 infection in specific high-risk groups. Antibodies cocktail has shown promising results in preventing progression to severe disease, but the real-world experience is still evolving. Herein, we present a retrospective analysis of 22 patients who were administered the antibodies cocktail between August 2021 and March 2022 at our tertiary care center. METHODS: We conducted an observational retrospective analysis of clinicoradiological, inflammatory parameters, progression of the disease, and outcome among 22 mild and moderate COVID-19 patients treated with antibodies cocktail. RESULTS: The mean age was 67.7 years (SD ± 18.3) and comprised of 13 males (59%), while 9 were females (40.9%). Nine (40.9%) patients were fully vaccinated with two doses, nine (40.9%) were partially vaccinated with one dose while four patients (18.2%) were unvaccinated, and the rest were unvaccinated. Diabetes and hypertension were the commonest comorbidities; hematological and solid organ malignancies were other comorbidities. Eight patients had radiological opacities consistent with COVID-19 pneumonia and had shown significant regression in four patients after the therapy. None of our patients required supplemental oxygen or progressed to severe acute respiratory distress syndrome. All patients were discharged in a stable condition within 6 days of the therapy. CONCLUSIONS: The neutralizing antibodies cocktail has shown encouraging results in our analysis in preventing progression to severe disease in patients with high-risk conditions.
format Online
Article
Text
id pubmed-10193195
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd.
record_format MEDLINE/PubMed
spelling pubmed-101931952023-05-18 Real-world experience of monoclonal antibodies in mild-to-moderate COVID-19 patients at a tertiary care center Marwah, Vikas Choudhary, Robin Adhikari, Sudipt Pemmaraju, Arpita Menon, A.S. Manrai, Manish Ajai Kumar, Tentu Verma, Shipra Med J Armed Forces India Original Article BACKGROUND: Neutralizing antibodies cocktail (casirivimab and imdevimab) has received emergency use authorization recommendation by Food and Drug Administration (FDA) and WHO for mild-to-moderate COVID-19 infection in specific high-risk groups. Antibodies cocktail has shown promising results in preventing progression to severe disease, but the real-world experience is still evolving. Herein, we present a retrospective analysis of 22 patients who were administered the antibodies cocktail between August 2021 and March 2022 at our tertiary care center. METHODS: We conducted an observational retrospective analysis of clinicoradiological, inflammatory parameters, progression of the disease, and outcome among 22 mild and moderate COVID-19 patients treated with antibodies cocktail. RESULTS: The mean age was 67.7 years (SD ± 18.3) and comprised of 13 males (59%), while 9 were females (40.9%). Nine (40.9%) patients were fully vaccinated with two doses, nine (40.9%) were partially vaccinated with one dose while four patients (18.2%) were unvaccinated, and the rest were unvaccinated. Diabetes and hypertension were the commonest comorbidities; hematological and solid organ malignancies were other comorbidities. Eight patients had radiological opacities consistent with COVID-19 pneumonia and had shown significant regression in four patients after the therapy. None of our patients required supplemental oxygen or progressed to severe acute respiratory distress syndrome. All patients were discharged in a stable condition within 6 days of the therapy. CONCLUSIONS: The neutralizing antibodies cocktail has shown encouraging results in our analysis in preventing progression to severe disease in patients with high-risk conditions. Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd. 2023-05-18 /pmc/articles/PMC10193195/ /pubmed/37360888 http://dx.doi.org/10.1016/j.mjafi.2023.03.006 Text en © 2023 Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Marwah, Vikas
Choudhary, Robin
Adhikari, Sudipt
Pemmaraju, Arpita
Menon, A.S.
Manrai, Manish
Ajai Kumar, Tentu
Verma, Shipra
Real-world experience of monoclonal antibodies in mild-to-moderate COVID-19 patients at a tertiary care center
title Real-world experience of monoclonal antibodies in mild-to-moderate COVID-19 patients at a tertiary care center
title_full Real-world experience of monoclonal antibodies in mild-to-moderate COVID-19 patients at a tertiary care center
title_fullStr Real-world experience of monoclonal antibodies in mild-to-moderate COVID-19 patients at a tertiary care center
title_full_unstemmed Real-world experience of monoclonal antibodies in mild-to-moderate COVID-19 patients at a tertiary care center
title_short Real-world experience of monoclonal antibodies in mild-to-moderate COVID-19 patients at a tertiary care center
title_sort real-world experience of monoclonal antibodies in mild-to-moderate covid-19 patients at a tertiary care center
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193195/
https://www.ncbi.nlm.nih.gov/pubmed/37360888
http://dx.doi.org/10.1016/j.mjafi.2023.03.006
work_keys_str_mv AT marwahvikas realworldexperienceofmonoclonalantibodiesinmildtomoderatecovid19patientsatatertiarycarecenter
AT choudharyrobin realworldexperienceofmonoclonalantibodiesinmildtomoderatecovid19patientsatatertiarycarecenter
AT adhikarisudipt realworldexperienceofmonoclonalantibodiesinmildtomoderatecovid19patientsatatertiarycarecenter
AT pemmarajuarpita realworldexperienceofmonoclonalantibodiesinmildtomoderatecovid19patientsatatertiarycarecenter
AT menonas realworldexperienceofmonoclonalantibodiesinmildtomoderatecovid19patientsatatertiarycarecenter
AT manraimanish realworldexperienceofmonoclonalantibodiesinmildtomoderatecovid19patientsatatertiarycarecenter
AT ajaikumartentu realworldexperienceofmonoclonalantibodiesinmildtomoderatecovid19patientsatatertiarycarecenter
AT vermashipra realworldexperienceofmonoclonalantibodiesinmildtomoderatecovid19patientsatatertiarycarecenter